Brooks Moore & Associates’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.26M | Buy |
28,842
+1,425
| +5% | +$307K | 3.26% | 8 |
|
|
2026
Q1 | $5.96M | Sell |
27,417
-1,050
| -4% | -$233K | 2.99% | 10 |
|
|
2025
Q4 | $6.5M | Buy |
28,467
+175
| +0.6% | +$39.9K | 3.2% | 7 |
|
|
2025
Q3 | $6.55M | Sell |
28,292
-200
| -0.7% | -$40.7K | 3.32% | 4 |
|
|
2025
Q2 | $5.39M | Buy |
28,492
+149
| +0.5% | +$27.7K | 2.91% | 6 |
|
|
2025
Q1 | $5.94M | Sell |
28,343
-200
| -0.7% | -$38.9K | 3.35% | 4 |
|
|
2024
Q4 | $5.07M | Hold |
28,543
| – | – | 3% | 7 |
|
|
2024
Q3 | $5.64M | Sell |
28,543
-153
| -0.5% | -$28.6K | 3.33% | 5 |
|
|
2024
Q2 | $4.92M | Hold |
28,696
| – | – | 3.17% | 9 |
|
|
2024
Q1 | $5.23M | Sell |
28,696
-85
| -0.3% | -$14.6K | 3.35% | 7 |
|
|
2023
Q4 | $4.46M | Sell |
28,781
-200
| -0.7% | -$29.2K | 3.07% | 9 |
|
|
2023
Q3 | $4.32M | Sell |
28,981
-1,349
| -4% | -$198K | 3.26% | 7 |
|
|
2023
Q2 | $4.09M | Sell |
30,330
-488
| -2% | -$71.6K | 2.88% | 10 |
|
|
2023
Q1 | $4.91M | Buy |
30,818
+585
| +2% | +$89.4K | 3.53% | 5 |
|
|
2022
Q4 | $4.89M | Sell |
30,233
-6,713
| -18% | -$1.03M | 3.57% | 7 |
|
|
2022
Q3 | $4.96M | Buy |
36,946
+892
| +2% | +$128K | 4.01% | 3 |
|
|
2022
Q2 | $5.52M | Sell |
36,054
-1,534
| -4% | -$234K | 3.98% | 2 |
|
|
2022
Q1 | $6.09M | Sell |
37,588
-2,800
| -7% | -$407K | 3.74% | 2 |
|
|
2021
Q4 | $5.47M | Buy |
40,388
+1,060
| +3% | +$125K | 3.21% | 3 |
|
|
2021
Q3 | $4.24M | Sell |
39,328
-4,645
| -11% | -$531K | 2.78% | 5 |
|
|
2021
Q2 | $4.95M | Sell |
43,973
-375
| -0.8% | -$42.2K | 3.16% | 3 |
|
|
2021
Q1 | $4.8M | Buy |
44,348
+2,375
| +6% | +$254K | 3.25% | 4 |
|
|
2020
Q4 | $4.5M | Buy |
41,973
+2,066
| +5% | +$199K | 3.48% | 4 |
|
|
2020
Q3 | $3.5M | Buy |
39,907
+6,719
| +20% | +$633K | 3.01% | 5 |
|
|
2020
Q2 | $3.26M | Buy |
33,188
+2,371
| +8% | +$209K | 3.05% | 5 |
|
|
2020
Q1 | $2.35M | Buy |
30,817
+2,110
| +7% | +$180K | 2.49% | 9 |
|
|
2019
Q4 | $2.54M | Buy |
28,707
+1
| +0% | +$83 | 2.02% | 15 |
|
|
2019
Q3 | $2.17M | Buy |
28,706
+7,924
| +38% | +$543K | 1.84% | 19 |
|
|
2019
Q2 | $1.51M | Buy |
20,782
+3,175
| +18% | +$250K | 1.3% | 29 |
|
|
2019
Q1 | $1.42M | Buy |
17,607
+1,200
| +7% | +$98.2K | 1.29% | 31 |
|
|
2018
Q4 | $1.51M | Buy |
+16,407
| New | +$1.44M | 1.52% | 24 |
|
Other funds holding ABBV
Brooks Moore & Associates's ABBV Position: Q2 2026 in Review
Brooks Moore & Associates increased its AbbVie (ABBV) stake by 5.2% in Q2 2026, buying an estimated $307K and bringing the position to 28,842 shares worth $7.26M. The position accounts for 3.26% of the portfolio, ranked #8.
Brooks Moore & Associates first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. 4,221 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Brooks Moore & Associates held 28,842 shares of AbbVie worth $7.26M as of Q2 2026.
- Brooks Moore & Associates bought 1,425 AbbVie shares in Q2 2026, an estimated $307K.
- AbbVie made up 3.26% of Brooks Moore & Associates's portfolio in Q2 2026, its #8 holding.
- Brooks Moore & Associates first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
- 4,221 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Brooks Moore & Associates's 13F filing for Q2 2026, filed 17 Aug 2026.